Stock Events

Stock Events

Ascendis Pharma A/S 

$238.66
45
-$7.4-3.01% Friday 20:00

Statistics

Day High
250
Day Low
236.22
52W High
249.84
52W Low
151.25
Volume
668,714
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Q1 2026
Next
-1.89
2.49
6.88
11.26
Expected EPS
1.41606494298
Actual EPS
N/A

Financials

-31.32%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.68BRevenue
-526.7MNet Income

Analyst Ratings

287.38Average Price Target
The highest estimate is 326.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASND. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap194.57B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap862.01B
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap107.83B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap830.6M
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap2.77B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap178B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Show more...
CEO
Mr. Jan Moller Mikkelsen
Employees
1017
Country
Denmark
ISIN
DK0060615755

Listings

STU
DE
A710.STU
STU
DE
A71.STU
MU
DE
A710.MU
MU
DE
A71.MU

0 Comments

Share your thoughts

FAQ

What is Ascendis Pharma A/S stock price today?▼
The current price of ASND is $238.66 USD — it has decreased by -3.01% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ascendis Pharma A/S stocks are traded under the ticker ASND.
Is Ascendis Pharma A/S stock price growing?▼
ASND stock has risen by +8.03% compared to the previous week, the month change is a -1.26% fall, over the last year Ascendis Pharma A/S has showed a +57.79% increase.
When is the next Ascendis Pharma A/S earnings date?▼
Ascendis Pharma A/S is going to release the next earnings report on August 06, 2026.
What were Ascendis Pharma A/S earnings last quarter?▼
ASND earnings for the last quarter are 11.26 USD per share, whereas the estimation was 0.19 USD resulting in a +5,909.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ascendis Pharma A/S revenue for the last year?▼
Ascendis Pharma A/S revenue for the last year amounts to 1.68B USD.
What is Ascendis Pharma A/S net income for the last year?▼
ASND net income for the last year is -526.7M USD.
How many employees does Ascendis Pharma A/S have?▼
As of May 09, 2026, the company has 1,017 employees.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Health & Wellness sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.
Where is Ascendis Pharma A/S headquartered?▼
Ascendis Pharma A/S is headquartered in Hellerup, Denmark.